Cancer drug dosing study could cut clinic visits in half

NCT ID NCT04295863

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two common cancer immunotherapy drugs (nivolumab and pembrolizumab) can be given less often than the current standard schedule. About 264 adults with advanced or metastatic cancer will be randomly assigned to receive the drugs at standard intervals or extended intervals. Researchers will compare drug levels in the blood to see if the extended schedule keeps levels high enough to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CANCER

Contacts and locations

Locations

SSM Health Cancer Care
RECRUITING

Madison, Wisconsin, 53717, United States
University Of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.